Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Cox

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Heart Rhythm|February 25, 2024
ECG-only explainable deep learning algorithm predicts the risk for malignant ventricular arrhythmia in phospholamban cardiomyopathyRutger R van de Leur, Remco de Brouwer, Hidde Bleijendaal, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Desmoglein-2 and desmocollin-2 mutations in dutch arrhythmogenic right ventricular dysplasia/cardiomypathy patients: results from a multicenter studyZahurul A Bhuiyan, Jan D H Jongbloed, Jasper van der Smagt, et al.
The American Journal of Cardiology|July 23, 2013
Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to revised 2010 task force criteria with inclusion of non-desmosomal phospholamban mutation carriersJudith A Groeneweg, Paul A van der Zwaag, Louise R A Olde Nordkamp, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|July 24, 2023
MYH7 p.(Arg1712Gln) is pathogenic founder variant causing hypertrophic cardiomyopathy with overall relatively delayed onsetLuisa Marsili, Freyja H M van Lint, Francesco Russo, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 19, 2019
The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status updateL P Bosman, T E Verstraelen, F H M van Lint, et al.
JACC. Heart Failure|August 9, 2025
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)-Positive IndividualsMyrthe Y C van der Heide, Tom E Verstraelen, Remco de Brouwer, et al.
Heart Rhythm|November 27, 2012
Remodeling of the cardiac sodium channel, connexin43, and plakoglobin at the intercalated disk in patients with arrhythmogenic cardiomyopathyMaartje Noorman, Sara Hakim, Elise Kessler, et al.
Circulation|May 25, 2011
Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up studyMoniek G P J Cox, Paul A van der Zwaag, Christian van der Werf, et al.
European Journal of Heart Failure|July 24, 2012
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathyPaul A van der Zwaag, Ingrid A W van Rijsingen, Angeliki Asimaki, et al.
European Heart Journal|May 20, 2023
A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriersRemco de Brouwer, Wouter P Te Rijdt, Edgar T Hoorntje, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Heart Rhythm|February 25, 2024
ECG-only explainable deep learning algorithm predicts the risk for malignant ventricular arrhythmia in phospholamban cardiomyopathyRutger R van de Leur, Remco de Brouwer, Hidde Bleijendaal, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Desmoglein-2 and desmocollin-2 mutations in dutch arrhythmogenic right ventricular dysplasia/cardiomypathy patients: results from a multicenter studyZahurul A Bhuiyan, Jan D H Jongbloed, Jasper van der Smagt, et al.
The American Journal of Cardiology|July 23, 2013
Arrhythmogenic right ventricular dysplasia/cardiomyopathy according to revised 2010 task force criteria with inclusion of non-desmosomal phospholamban mutation carriersJudith A Groeneweg, Paul A van der Zwaag, Louise R A Olde Nordkamp, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|July 24, 2023
MYH7 p.(Arg1712Gln) is pathogenic founder variant causing hypertrophic cardiomyopathy with overall relatively delayed onsetLuisa Marsili, Freyja H M van Lint, Francesco Russo, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|April 19, 2019
The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status updateL P Bosman, T E Verstraelen, F H M van Lint, et al.
JACC. Heart Failure|August 9, 2025
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)-Positive IndividualsMyrthe Y C van der Heide, Tom E Verstraelen, Remco de Brouwer, et al.
Heart Rhythm|November 27, 2012
Remodeling of the cardiac sodium channel, connexin43, and plakoglobin at the intercalated disk in patients with arrhythmogenic cardiomyopathyMaartje Noorman, Sara Hakim, Elise Kessler, et al.
Circulation|May 25, 2011
Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up studyMoniek G P J Cox, Paul A van der Zwaag, Christian van der Werf, et al.
European Journal of Heart Failure|July 24, 2012
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathyPaul A van der Zwaag, Ingrid A W van Rijsingen, Angeliki Asimaki, et al.
European Heart Journal|May 20, 2023
A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriersRemco de Brouwer, Wouter P Te Rijdt, Edgar T Hoorntje, et al.
Pageof 14